Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 442Rectal Neoplasms 209Colonic Neoplasms 202Pancreatic Neoplasms 133Stomach Neoplasms 117Neoplasm Metastasis 86Esophageal Neoplasms 57Carcinoma, Hepatocellular 41Adenocarcinoma Of Esophagus 37Neoplasms 36Cholangiocarcinoma 27Biliary Tract Neoplasms 23Gastrointestinal Neoplasms 20Gallbladder Neoplasms 20Adenocarcinoma 19Carcinoma, Non-Small-Cell Lung 16Esophageal Squamous Cell Carcinoma 15Liver Neoplasms 14Bile Duct Neoplasms 14Digestive System Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Colorectal Cancer Metastatic 8Appendiceal Neoplasms 7Peritoneal Neoplasms 6Ovarian Neoplasms 6Intestinal Neoplasms 6Carcinoma 6Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Renal Cell 5

Interventions

Gemcitabine 4pembrolizumab 3napabucasin 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2Taxes 2Sunitinib 2Sorafenib 2Paclitaxel 2Leucovorin 2Fluorouracil 2Cisplatin 2Bevacizumab 2pralsetinib 1linifanib 1durvalumab 1Radiofrequency Ablation 1Pemetrexed 1Nivolumab 1Immunotherapy 1Endoscopic Mucosal Resection 1Cobicistat 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Leucovorin × Gastrointestinal × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡